Brief: Imvigor011 Bladder Cancer Trial Achieves Positive Results, With Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
18/08/2025 14:25
Natera Inc NTRA.O: IMVIGOR011 BLADDER CANCER TRIAL ACHIEVES POSITIVE RESULTS, WITH SIGNATERA™ STRONGLY PREDICTING ADJUVANT IMMUNOTHERAPY BENEFIT NATERA INC - SIGNATERA-POSITIVE PATIENTS SHOW IMPROVED SURVIVAL WITH ATEZOLIZUMAB NATERA INC - TO FINALIZE FDA APPLICATION FOR SIGNATERA Source text: ID:nBw35JKmZa Further company coverage: NTRA.O
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers